Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

Tamoxifen is the standard first-line hormonal therapy for premenopausal women with estrogen receptor (ER)-positive metastatic breast cancer (BC). One of the crucial mechanisms underlying hormonal therapy resistance is the collateral activation of the phosphatidylinositol-3 kinase (PI3K)/AKT pathway....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, I-Chun, Hsiao, Li-Ping, Huang, I-Wen, Yu, Huei-Chieh, Yeh, Ling-Chun, Lin, Ching-Hung, Wei-Wu Chen, Tom, Cheng, Ann-Lii, Lu, Yen-Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574981/
https://www.ncbi.nlm.nih.gov/pubmed/28852212
http://dx.doi.org/10.1038/s41598-017-10555-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574981/
https://www.ncbi.nlm.nih.gov/pubmed/28852212
http://dx.doi.org/10.1038/s41598-017-10555-z

Ejemplares similares